Melbourne, Australia, and San Francisco, USA, Sept. 19th, 2017 – Telix Pharmaceuticals Limited (“Telix”) is pleased to announce the conclusion of a collaboration and licensing agreement with CellSight Technologies, Inc. for the VisAcT immunoPET imaging technology. To read the full press release click here.